SCHEMBL18779446

SCHEMBL18779446

Cc1ccc(C(=O)c2ccc(C(=O)O)cc2[N+](=O)[O-])cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.62
MAPT P10636 3/20 0.59
ALDH1A1 P00352 2/20 0.59
HTT P42858 1/20 0.59
CASP6 P55212 2/20 0.58
HCAR3 P49019 6/20 0.57
ABCC3 O15438 1/20 0.57
ABCC4 O15439 1/20 0.57
NR1I2 O75469 1/20 0.57
ABCB11 O95342 1/20 0.57
TTR P02766 1/20 0.57
NR3C1 P04150 1/20 0.57
PGR P06401 1/20 0.57
HTR1A P08908 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
RARB P10826 1/20 0.57
COMT P21964 1/20 0.57
SLC6A2 P23975 1/20 0.57
ADORA1 P30542 1/20 0.57
ADRA1A P35348 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11298968 0.89 ALDH1A1 (0.63) TSHRMAPTALDH1A1HTTCASP6
SCHEMBL27605479 0.88 CASP6 (0.62) TSHRALDH1A1CASP6HCAR3LMNA
SCHEMBL18779475 0.85 CASP6 (0.58) TSHRALDH1A1CASP6HCAR3TTR
SCHEMBL7263800 0.83 ALDH1A1 (0.56) TSHRMAPTALDH1A1HTTABCC3
SCHEMBL30810715 0.82 CASP6 (0.72) TSHRCASP6HCAR3LMNAPOLB
SCHEMBL842661 0.82 CASP6 (0.72) TSHRCASP6HCAR3LMNAPOLB
SCHEMBL145092 0.82 CASP6 (0.72) TSHRCASP6HCAR3LMNAPOLB
SCHEMBL18779429 0.82 KMT2A (0.58) MAPTALDH1A1HTTABCC3ABCC4
Methyl Alcohol SCHEMBL28215594 0.82 ALDH1A1 (0.55) TSHRMAPTALDH1A1HTTABCC3
SCHEMBL15808913 0.81 TSHR (0.71) TSHRCASP6HCAR3LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170114062-A1 BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2017-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114062-A1 BENZAMIDE OR BENZAMINE COMPOUNDS USEFUL AS ANTICANCER AGENTS FOR THE TREATMENT OF HUMAN CANCERS ACAT1, ACAT2, NPC1L1 TSHR 4433/4885MAPT 4323/4885ALDH1A1 1313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.